Literature DB >> 19452572

Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Albert J Czaja1, Yusuf Bayraktar.   

Abstract

Non-classical manifestations of autoimmune hepatitis can delay diagnosis and treatment. Our aims were to describe the clinical phenotypes that can confound the diagnosis, detail scoring systems that can ensure their recognition, and outline advances in treatment that can improve their outcome. Prime source and review articles in English were selected through Medline from 1970-2008 and assimilated into personal libraries spanning 32 years. Acute severe or asymptomatic presentations and atypical histological findings, including centrilobular zone 3 necrosis and concurrent bile duct changes, are compatible with the diagnosis. Cholangiographic abnormalities may be present in children and adults with the disease, and autoimmune hepatitis must be considered in patients without autoantibodies or with antimitochondrial antibodies and no other cholestatic features. Asymptomatic patients frequently become symptomatic; mild disease can progress; and there are no confident indices that justify withholding treatment. Two diagnostic scoring systems with complementary virtues have been developed to evaluate patients with confusing features. Normal liver tests and tissue constitute the optimal end point of treatment, and the first relapse is an indication for long-term azathioprine therapy. Cyclosporine, tacrolimus and mycophenolate mofetil are promising salvage therapies, and budesonide with azathioprine may be a superior frontline treatment. We conclude that the non-classical phenotypes of autoimmune hepatitis can be recognized promptly, diagnosed accurately, and treated effectively.

Entities:  

Mesh:

Year:  2009        PMID: 19452572      PMCID: PMC2684596          DOI: 10.3748/wjg.15.2314

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  211 in total

1.  Echinacea-induced severe acute hepatitis with features of cholestatic autoimmune hepatitis.

Authors:  Orhan Kocaman; Sadettin Hulagu; Omer Senturk
Journal:  Eur J Intern Med       Date:  2007-08-09       Impact factor: 4.487

2.  Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis.

Authors:  Mehdi Mohamadnejad; Reza Malekzadeh; Siavosh Nasseri-Moghaddam; Sepideh Hagh-Azali; Nasser Rakhshani; Seyed Mohamad Tavangar; Mojtaba Sedaghat; Seyed Meysam Alimohamadi
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

3.  Alteration in suppressor cell activity in chronic active hepatitis.

Authors:  H J Hodgson; J R Wands; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

4.  Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis.

Authors:  J Rebollo Bernárdez; C Cifuentes Mimoso; A Piñar Moreno; A Caunedo Alvarez; E Salas Herrero; M Jiménez-Sáenz; J Herrerías Gutiérrez
Journal:  Rev Esp Enferm Dig       Date:  1999-09       Impact factor: 2.086

5.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

6.  Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.

Authors:  A J Czaja; S J Beaver; M T Shiels
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

7.  Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004.

Authors:  Yvonne N Flores; Hal F Yee; Mei Leng; José J Escarce; Roshan Bastani; Jorge Salmerón; Leo S Morales
Journal:  Am J Gastroenterol       Date:  2008-07-30       Impact factor: 10.864

8.  Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis.

Authors:  E J Viruet; E A Torres
Journal:  P R Health Sci J       Date:  1998-09       Impact factor: 0.705

9.  Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.

Authors:  Aldo J Montano-Loza; Herschel A Carpenter; Albert J Czaja
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

10.  Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis.

Authors:  Aldo J Montano-Loza; Herschel A Carpenter; Albert J Czaja
Journal:  J Clin Gastroenterol       Date:  2008-10       Impact factor: 3.062

View more
  9 in total

Review 1.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

Review 2.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 3.  Challenges in the diagnosis and management of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Can J Gastroenterol       Date:  2013-09       Impact factor: 3.522

4.  Centrilobular necrosis in acute presentation of Japanese patients with type 1 autoimmune hepatitis.

Authors:  Kazumichi Abe; Yukiko Kanno; Ken Okai; Fumiko Katsushima; Kyoko Monoe; Hironobu Saito; Atsushi Takahashi; Junko Yokokawa; Hiromasa Ohira
Journal:  World J Hepatol       Date:  2012-09-27

Review 5.  Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

Review 6.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

Review 7.  Autoimmune enteropathy with a CD8+ CD7- T-cell small bowel intraepithelial lymphocytosis: case report and literature review.

Authors:  Shrinivas Bishu; Violeta Arsenescu; Eun Y Lee; H David Vargas; Willem J S de Villiers; Razvan Arsenescu
Journal:  BMC Gastroenterol       Date:  2011-11-29       Impact factor: 3.067

8.  Autoimmune Hepatitis with Acute Presentation: Clinical, Biochemical, and Histological Features of 126 Patients.

Authors:  Álvaro Urzúa; Carolina Pizarro; Abraham Gajardo; Rafael Poniachik; Claudia Pavez; Máximo Cattaneo; Javier Brahm; Laura Carreño; Jaime Poniachik
Journal:  Can J Gastroenterol Hepatol       Date:  2022-09-26

Review 9.  Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions.

Authors:  Albert J Czaja
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.